GeoVax CEO to Present at ROTH Healthcare Conference, Highlighting Vaccine Pipeline Progress

GeoVax Labs, Inc. announced that Chairman and CEO David Dodd will participate in the 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025, at the Yale Club in New York City. The invite-only event connects healthcare companies with institutional investors through one-on-one meetings and panel discussions, offering executives a platform to discuss company strategies and pipeline developments.

Dodd will be available throughout the day to meet with investors and discuss GeoVax's clinical progress across multiple vaccine platforms. The company's pipeline includes GEO-MVA, an MVA-based Mpox and smallpox vaccine that recently received favorable Scientific Advice from the European Medicines Agency. This regulatory guidance positions the vaccine to potentially advance directly to Phase 3 clinical evaluation, bypassing earlier trial phases and accelerating its development timeline for global preparedness and stockpile strategies.

Another key program is GEO-CM04S1, GeoVax's multi-antigen COVID-19 vaccine currently undergoing evaluation in three Phase 2 clinical trials. These trials span various patient populations, including immunocompromised individuals and healthy adults. The vaccine is being tested as both a primary vaccine for patients with hematologic cancers and other conditions where current authorized vaccines prove insufficient, and as a booster for chronic lymphocytic leukemia patients and healthy individuals previously vaccinated with mRNA vaccines.

In oncology, GeoVax is advancing Gedeptin®, a gene-directed enzyme prodrug therapy for solid tumors. The company plans to initiate a Phase 2 trial focusing on head and neck cancer, building on completed multicenter Phase 1/2 clinical trials for advanced head and neck cancers. This therapeutic approach represents an innovative strategy in cancer treatment that could address unmet medical needs in oncology.

The conference participation comes at a critical time for GeoVax as the company navigates multiple clinical development pathways simultaneously. The ROTH Healthcare Opportunities Conference format, featuring 25-minute management-investor meetings, provides institutional clients with extensive interaction opportunities to gain in-depth insights into each company's strategy and upcoming milestones. For more information about GeoVax's clinical trials and technology platform, visit https://www.geovax.com.

GeoVax's broad pipeline addressing both infectious diseases and cancer reflects the evolving landscape of biotechnology development, where companies are increasingly pursuing multiple therapeutic areas. The company's progress in vaccine development comes amid ongoing global health challenges, including emerging infectious diseases and the need for improved cancer treatments. The favorable EMA regulatory advice for the Mpox/smallpox vaccine indicates potential regulatory pathways that could accelerate vaccine availability for public health preparedness.

For investors, GeoVax's participation in high-profile conferences like the ROTH Healthcare Opportunities event provides visibility into the company's clinical progress and strategic direction. The multiple Phase 2 trials for the COVID-19 vaccine and planned Phase 2 trial for Gedeptin represent significant milestones that could shape the company's valuation and partnership opportunities. The conference serves as an important venue for healthcare companies to communicate their value proposition to the investment community during a period of increased scrutiny on biotech funding and clinical validation.